+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 2Years - 17Years
All Genders
ID07298421

Evaluating Afimkibart IV and SC Therapy for Induction and Maintenance in Children Ages 2 to 17 With Moderate to Severe Crohns Disease

Led by Hoffmann-La Roche · Updated on 2026-10-06

100

Participants Needed

17

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Afimkibart also called RO7790121 in children aged 2 to 17 years who have moderately to severely active Crohns Disease. This phase III, double-blind, multi-center study aims to assess the drugs effectiveness and safety as both induction and maintenance therapy for this condition. Participants will be randomly assigned to receive one of two dose groups of Afimkibart. The treatment starts with intravenous IV infusion followed by subcutaneous SC injections. The study compares these two dosing regimens to monitor their effects over time. Throughout the trial, participants will be monitored for clinical remission using the Pediatric Crohns Disease Activity Index and endoscopic response at Week 52. Researchers will also track other outcomes related to Crohns disease activity, inflammation markers, and safety measures over approximately 5.5 years. Study visits and assessments will evaluate the drug concentration in the blood and the incidence of adverse events.

CONDITIONS

Brief Title

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

Research Team

R

Reference Study ID Number: CP45906 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here